Organization
Georgetown University Medical Center
20 abstracts
Abstract
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.Org: University of Oxford, Centre for Public Health, Karolinska Institutet, Fred Hutchinson Cancer Research Center, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.Org: NSABP, Dana-Farber Cancer Institute, University of Michigan Health System Comprehensive Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Institute of Cancer Research,
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE).Org: Medstar Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Lombardi Cancer Center Georgetown University, Regional Cancer Care Associates, Cantex Pharmaceuticals, Georgetown University Medical Center,
Abstract
Pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib (ribo) in Black patients with metastatic breast cancer (mBC): The LEANORA study.Org: Georgetown University Medical Center, Washington, DC, Tufts Medical Center/Tufts University, Boston, MA, National Cancer Institute/National Institutes of Health,
Abstract
Developing behavioral intervention to support molecular testing of patients with biliary tract cancer.Org: Georgetown University, Lombardi Comprehensive Cancer Center, Lewis Katz School of Medicine, Center for Discovery & Innovation, Hackensack Meridian Health,
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Abstract
Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence.Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health,
Abstract
Immune-related adverse event prediction and influential factor identification.Org: Georgetown University Medical Center, Washington, DC, Georgetown Lombardi Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.Org: Memorial Sloan Kettering Cancer Center, Stanford University Medical Center, Stanford, CA, Seoul National University Bundang Hospital, START Midwest, Grand Rapids, MI, Samsung Medical Center,
Abstract
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data.Org: Samuel Oschin Comprehensive Cancer Center, Department of Hematology, Mayo Clinic Rochester, Janssen Global Market Access, Janssen Scientific Affairs, Georgetown University Medical Center,
Abstract
Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, Department of Preventive Medicine,
Abstract
Comprehensive profiling of clock genes expression in hepatocellular carcinoma (HCC).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, Lawrence J. Ellison Institute for Transformative Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA,
Abstract
Clinical genomic implications of transcriptional subtypes in pancreatic cancer.Org: Dana-Farber Cancer Institute, Brookline, MA, Boston, MA, Caris Life Sciences, Irving, TX, Phoenix, AZ,
Abstract
Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC).Org: Caris Life Sciences, Irving, TX, West Virginia University Cancer Institute, Mary Babb Randolph Cancer Center, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center,
Abstract
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.Org: Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, Fox Chase Cancer Center, Temple University Health System,
Abstract
Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.Org: Vanderbilt University School of Medicine, Massachusetts General Hospital, Melanoma Institute Australia, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, Georgetown University Medical Center,
Abstract
A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.Org: Virginia Cancer Specialists, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,
Abstract
Microscopic residual disease (MRD) monitoring and time to disease recurrence across gastrointestinal (GI) malignancies: A single-institution, real-world study.Org: MedStar Georgetown University Hospital, Lombardi Cancer Center MedStar Georgetown University Hospital, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,
Abstract
The roles of race and social determinants of health in pancreatic adenocarcinoma diagnosis and treatment.Org: Georgetown University Medical Center, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Georgetown University Medical School,